What is the expected growth forecast for the market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driving the future outlook.

What are the key drivers of the Cell Therapy and Tissue Engineering market?

Increasing demand for regenerative medicine and advancements in technology are key drivers of the market.

What are the major challenges facing the Cell Therapy and Tissue Engineering market?

High development costs and stringent regulatory requirements are major challenges facing the market.

Which regions are leading the Cell Therapy and Tissue Engineering market?

North America and Europe are currently the leading regions in the Cell Therapy and Tissue Engineering market.

Who are the top companies in the Cell Therapy and Tissue Engineering market?

Top companies include Johnson & Johnson, Pfizer, and Novartis, driving innovation and growth.

What future opportunities exist in the Cell Therapy and Tissue Engineering market?

Emerging applications in cardiology and neurology are expected to create new opportunities for market growth.

How is technology impacting the Cell Therapy and Tissue Engineering market?

Advances in gene editing and 3D printing are significantly impacting the market, enabling new treatments.

What is the current regulatory landscape for the Cell Therapy and Tissue Engineering market?

The regulatory landscape is evolving, with the FDA and EMA playing key roles in shaping the market's future outlook.

How will the Cell Therapy and Tissue Engineering market size change in the next 5 years?

The market size is expected to increase significantly, driven by growing demand and technological advancements.

Cell Therapy and Tissue Engineering Market: Opportunity by 2034 | In-Depth Report

Cell Therapy and Tissue Engineering by Application (Cell Defects, Genetic Diseases, Neurodegenerative Diseases, Tissue Malignancies, Others), by Types (Cell Therapy, Tissue Engineering), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cell Therapy and Tissue Engineering Market Size | CAGR 15.2 Forecast 2033

Cell Therapy and Tissue Engineering Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $12000 million

CAGR: 15.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cell Therapy and Tissue Engineering Market Overview

The Cell Therapy and Tissue Engineering market refers to the industry involved in the development and application of cell-based therapies and tissue engineering techniques to repair or replace damaged tissues and organs. As a rapidly evolving field, the Cell Therapy and Tissue Engineering market size is expected to experience significant growth, driven by advances in growth outlook, market forecast, and industry expansion. The scope of this market encompasses various types of cell therapies, including autologous and allogenic therapies, as well as tissue engineering techniques, such as biomaterials and bioactive molecules. The current Cell Therapy and Tissue Engineering market size is estimated to be around $15.6 billion, with a projected growth forecast of 14.5% CAGR from 2026 to 2033, driven by macro drivers such as increasing demand for regenerative therapies and technological advancements.

Loading chart…

The Cell Therapy and Tissue Engineering market is shaped by several key forces, including technology shifts, such as the development of novel biomaterials and bioactive molecules, regulations, such as those related to cell therapy manufacturing and approval, and consumer behavior, such as increasing demand for personalized therapies. The largest region in the Cell Therapy and Tissue Engineering market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific region, driven by increasing investment in regenerative medicine and growing demand for cell therapies. Overall, the Cell Therapy and Tissue Engineering market is expected to experience significant growth and expansion over the forecast period, driven by advances in technology, increasing demand, and evolving regulatory landscapes.

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Betalin Therapeutics; BioCardia, Inc.; BioReliance Corporation; Biosolution Co.; Brainstorm Cell Therapeutics, Inc.; MaxCyte, Inc.; Medigene AG; MEDIPOST CO.; Mesoblast Limited; Miromatrix Medical, Inc.; MolMed S.p.A; Mustang Bio, Inc.; NantKwest, Inc.; Neuralstem, Inc.; NexImmune, Inc.; Nohla Therapeutics, Inc.; ReNeuron Group plc; Richter-Helm BioLogics GmbH & Co. KG; RoosterBio, Inc.; RoslinCT; Rubius Therapeutics, Inc.; Sangamo Therapeutics, Inc.; Voyager Therapeutics, Inc.; Waisman Biomanufacturing; WindMIL Therapeutics, Inc.; Wuxi App Tec, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cell Therapy and Tissue Engineering market is experiencing significant growth, driven by various factors. The market dynamics are influenced by several key elements that impact the Cell Therapy and Tissue Engineering market size and growth forecast.

Growth Drivers2 items

Advancements in technology, such as gene editing and cell therapy, are enabling the development of innovative treatments, driving growth in the Cell Therapy and Tissue Engineering market.

Increasing demand for regenerative medicine and tissue engineering solutions is also fueling the growth of the market, with the growth forecast indicating a significant increase in the Cell Therapy and Tissue Engineering market size.

Restraints2 items

High development costs and stringent regulatory requirements are restraining the growth of the Cell Therapy and Tissue Engineering market, making it challenging for new entrants to penetrate the market.

Limited awareness and understanding of cell therapy and tissue engineering among patients and healthcare professionals are also hindering the adoption of these therapies, impacting the growth forecast.

Opportunities2 items

The increasing focus on personalized medicine and targeted therapies is creating opportunities for the development of innovative cell therapy and tissue engineering solutions.

Collaborations and partnerships between industry players, research institutions, and government organizations are also driving growth in the Cell Therapy and Tissue Engineering market, enabling the development of new treatments and therapies.

Challenges2 items

Ensuring the safety and efficacy of cell therapy and tissue engineering products is a significant challenge, requiring rigorous testing and regulatory compliance.

Managing the high costs associated with the development and commercialization of these therapies is also a challenge, making it essential to develop sustainable pricing strategies to ensure the long-term viability of the Cell Therapy and Tissue Engineering market.

Market Segmentation

Loading chart…

The Cell Therapy market can be segmented based on application and types. In terms of application, cell therapy is used to treat various diseases, including cardiovascular, neurological, and immunological disorders. The types of cell therapy include autologous and allogenic cell therapies, which contribute to the overall market size. Understanding the Cell Therapy and Tissue Engineering segmentation is crucial for industry players to develop targeted strategies.

The Tissue Engineering market can also be segmented based on application and types. Tissue engineering applications include orthopedic, dental, and dermatological treatments. The types of tissue engineering include synthetic and natural tissue engineering, which have distinct market shares. Analyzing the market taxonomy of tissue engineering helps in identifying opportunities and challenges in the industry.

Cell Therapy and Tissue Engineering Segmentation Breakdown9 items

Application

Cell Defects

Genetic Diseases

Neurodegenerative Diseases

Tissue Malignancies

Others

Types

Cell Therapy

Tissue Engineering

Regional Insights

Loading chart…

The Cell Therapy and Tissue Engineering market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of cell therapies, favorable policies, and significant investments in research and development.

Key drivers for North America include a mature ecosystem, high infrastructure investment, and a large patient population. Europe's growth is fueled by demographics, with an aging population driving demand for regenerative therapies. Asia Pacific's growth is driven by investments in research, a large patient population, and increasing adoption of cell therapies. Latin America's growth is slower due to limited infrastructure, while the Middle East & Africa region is driven by government policies and increasing adoption of cell therapies.

The regional forecast indicates that the Cell Therapy and Tissue Engineering market will experience significant growth, with the Asia Pacific region expected to drive market growth. Key factors influencing this growth include government policies, increasing investments, and a growing ecosystem. As the market continues to evolve, understanding the regional dynamics will be crucial for stakeholders to navigate the Cell Therapy and Tissue Engineering market.

Competitive Landscape

The Cell Therapy and Tissue Engineering market is moderately consolidated, with a mix of global players and local/regional companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Cell Therapy and Tissue Engineering competitive landscape is characterized by high competition, with key players employing various strategies to differentiate themselves. Pricing, in particular, is a critical competitive lever, with companies seeking to balance revenue goals with affordability considerations for patients and payers.

Companies in this space are pursuing common strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay ahead. However, they face challenges like margin pressure, compliance costs, and supply chain risks, which can impact their ability to invest in innovation and growth initiatives. Competitive differentiation is key, with companies focusing on factors like technology, service model, channel strength, customization, and cost advantages to stand out. The following companies are pursuing distinct strategic focuses:

Betalin Therapeutics: regional expansion

BioCardia, Inc.: innovation pipeline

BioReliance Corporation: OEM tie-ups

Brainstorm Cell Therapeutics, Inc.: premium pricing

MaxCyte, Inc.: vertical integration

Medigene AG: local manufacturing

Key Cell Therapy and Tissue Engineering Companies26 items

Betalin Therapeutics

BioCardia, Inc.

BioReliance Corporation

Biosolution Co.

Brainstorm Cell Therapeutics, Inc.

MaxCyte, Inc.

Medigene AG

MEDIPOST CO.

Mesoblast Limited

Miromatrix Medical, Inc.

MolMed S.p.A

Mustang Bio, Inc.

NantKwest, Inc.

Neuralstem, Inc.

NexImmune, Inc.

Nohla Therapeutics, Inc.

ReNeuron Group plc

Richter-Helm BioLogics GmbH & Co. KG

RoosterBio, Inc.

RoslinCT

Rubius Therapeutics, Inc.

Sangamo Therapeutics, Inc.

Voyager Therapeutics, Inc.

Waisman Biomanufacturing

WindMIL Therapeutics, Inc.

Wuxi App Tec, Inc.

Market Ecosystem

The Cell Therapy and Tissue Engineering ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three stages: upstream, where raw materials and technologies are developed; midstream, where these inputs are integrated into products; and downstream, where products are distributed to end users. Understanding the interactions and interdependencies within this ecosystem is crucial for a comprehensive value chain analysis.

Raw material/component suppliers — provide biomaterials and cells

Technology providers — develop cell processing and tissue engineering technologies

OEMs / manufacturers — produce cell therapy and tissue engineering products

System integrators / EPCs — integrate products into therapeutic solutions

Distributors / channel partners — deliver products to healthcare facilities

Regulators/standards bodies — establish and enforce industry standards

End users / buyers — healthcare providers and researchers utilizing cell therapies

The flow of value within the Cell Therapy and Tissue Engineering ecosystem is influenced by various control points, including regulatory approvals and standards set by governing bodies. Dependency risks, such as input constraints and the need for specialized technologies, can impact the ecosystem's efficiency. Furthermore, partnerships between participants, switching costs, and interoperability requirements can affect the adoption and diffusion of cell therapies and tissue engineering products. The ecosystem's dynamics can also vary by region, reflecting differences in regulatory frameworks, healthcare infrastructure, and market demand.

Recent Industry Insights

The Cell Therapy and Tissue Engineering industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated innovation in the field. Notable mergers and acquisitions have also taken place, with companies expanding their portfolios to include cell therapy and tissue engineering products. Furthermore, several product and technology launches have been announced, showcasing advancements in regenerative medicine.

Additionally, regulatory changes have been implemented to support the growth of the industry, with funding rounds and expansions providing necessary capital for research and development. A shift in consumer and enterprise trends has also been observed, with increased focus on personalized medicine and targeted therapies. These developments are expected to continue shaping the Cell Therapy and Tissue Engineering industry trends in the coming years.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Cell Therapy and Tissue Engineering market outlook. The market exhibits high attractiveness due to its potential to revolutionize the treatment of various diseases. The competitive intensity is moderate, with key players focusing on innovation and partnerships to gain a competitive edge. The long-term outlook is promising, driven by increasing demand for regenerative therapies.

The innovation landscape is rapidly evolving, with advancements in stem cell research and tissue engineering techniques. However, the demand-supply balance is a key concern, with a current shortage of available cell therapies. Key risk factors include regulatory challenges, high development costs, and potential safety concerns. Overall, the market presents opportunities for growth and investment, but careful consideration of these factors is essential for success.

11 items

1. Executive Summary

2. Cell Therapy and Tissue Engineering Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cell Therapy and Tissue Engineering Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cell Therapy and Tissue Engineering Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cell Defects

6.1.2. Genetic Diseases

6.1.3. Neurodegenerative Diseases

6.1.4. Tissue Malignancies

6.1.5. Others

6.2. Global Cell Therapy and Tissue Engineering Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Cell Therapy

6.2.2. Tissue Engineering

6.3. Global Cell Therapy and Tissue Engineering Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cell Therapy and Tissue Engineering Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cell Therapy and Tissue Engineering Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cell Therapy and Tissue Engineering Market Competition by Key Manufacturers

8.1. Global Cell Therapy and Tissue Engineering Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cell Therapy and Tissue Engineering: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Betalin Therapeutics

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BioCardia, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BioReliance Corporation

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biosolution Co.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Brainstorm Cell Therapeutics, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. MaxCyte, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Medigene AG

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. MEDIPOST CO.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Mesoblast Limited

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Miromatrix Medical, Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. MolMed S.p.A

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Mustang Bio, Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. NantKwest, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Neuralstem, Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. NexImmune, Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Nohla Therapeutics, Inc.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. ReNeuron Group plc

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Richter-Helm BioLogics GmbH & Co. KG

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. RoosterBio, Inc.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. RoslinCT

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Rubius Therapeutics, Inc.

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Sangamo Therapeutics, Inc.

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Voyager Therapeutics, Inc.

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Waisman Biomanufacturing

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. WindMIL Therapeutics, Inc.

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Wuxi App Tec, Inc.

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cell Therapy and Tissue Engineering Market

Figure 4: Global Cell Therapy and Tissue Engineering Market: Drivers

Figure 5: Global Cell Therapy and Tissue Engineering Market: Challenges

Figure 6: Global Cell Therapy and Tissue Engineering Market: Trends

Figure 7: Global Cell Therapy and Tissue Engineering Market: Opportunity

Figure 8: Global Cell Therapy and Tissue Engineering Market: Restraint

Figure 9: Global Cell Therapy and Tissue Engineering Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cell Therapy and Tissue Engineering Market Value (USD Million) By Region

Figure 15: Global Cell Therapy and Tissue Engineering Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cell Therapy and Tissue Engineering Market Value (USD Million) By Region

Figure 23: Global Cell Therapy and Tissue Engineering Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Cell Therapy and Tissue Engineering Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cell Therapy and Tissue Engineering Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cell Therapy and Tissue Engineering Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cell Therapy and Tissue Engineering Market Value (USD Million) By Region

Table 10: Global Cell Therapy and Tissue Engineering Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cell Therapy and Tissue Engineering Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cell Therapy and Tissue Engineering Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cell Therapy and Tissue Engineering Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Betalin Therapeutics Basic Information And Sales Area

Table 31: Betalin Therapeutics. Products Portfolio

Table 32: BioCardia, Inc. Basic Information And Sales Area

Table 33: BioCardia, Inc.. Products Portfolio

Table 34: BioReliance Corporation Basic Information And Sales Area

Table 35: BioReliance Corporation. Products Portfolio

Table 36: Biosolution Co. Basic Information And Sales Area

Table 37: Biosolution Co.. Products Portfolio

Table 38: Brainstorm Cell Therapeutics, Inc. Basic Information And Sales Area

Table 39: Brainstorm Cell Therapeutics, Inc.. Products Portfolio

Table 40: MaxCyte, Inc. Basic Information And Sales Area

Table 41: MaxCyte, Inc.. Products Portfolio

Table 42: Medigene AG Basic Information And Sales Area

Table 43: Medigene AG. Products Portfolio

Table 44: MEDIPOST CO. Basic Information And Sales Area

Table 45: MEDIPOST CO.. Products Portfolio

Table 46: Mesoblast Limited Basic Information And Sales Area

Table 47: Mesoblast Limited. Products Portfolio

Table 48: Miromatrix Medical, Inc. Basic Information And Sales Area

Table 49: Miromatrix Medical, Inc.. Products Portfolio

Table 50: MolMed S.p.A Basic Information And Sales Area

Table 51: MolMed S.p.A. Products Portfolio

Table 52: Mustang Bio, Inc. Basic Information And Sales Area

Table 53: Mustang Bio, Inc.. Products Portfolio

Table 54: NantKwest, Inc. Basic Information And Sales Area

Table 55: NantKwest, Inc.. Products Portfolio

Table 56: Neuralstem, Inc. Basic Information And Sales Area

Table 57: Neuralstem, Inc.. Products Portfolio

Table 58: NexImmune, Inc. Basic Information And Sales Area

Table 59: NexImmune, Inc.. Products Portfolio

Table 60: Nohla Therapeutics, Inc. Basic Information And Sales Area

Table 61: Nohla Therapeutics, Inc.. Products Portfolio

Table 62: ReNeuron Group plc Basic Information And Sales Area

Table 63: ReNeuron Group plc. Products Portfolio

Table 64: Richter-Helm BioLogics GmbH & Co. KG Basic Information And Sales Area

Table 65: Richter-Helm BioLogics GmbH & Co. KG. Products Portfolio

Table 66: RoosterBio, Inc. Basic Information And Sales Area

Table 67: RoosterBio, Inc.. Products Portfolio

Table 68: RoslinCT Basic Information And Sales Area

Table 69: RoslinCT. Products Portfolio

Table 70: Rubius Therapeutics, Inc. Basic Information And Sales Area

Table 71: Rubius Therapeutics, Inc.. Products Portfolio

Table 72: Sangamo Therapeutics, Inc. Basic Information And Sales Area

Table 73: Sangamo Therapeutics, Inc.. Products Portfolio

Table 74: Voyager Therapeutics, Inc. Basic Information And Sales Area

Table 75: Voyager Therapeutics, Inc.. Products Portfolio

Table 76: Waisman Biomanufacturing Basic Information And Sales Area

Table 77: Waisman Biomanufacturing. Products Portfolio

Table 78: WindMIL Therapeutics, Inc. Basic Information And Sales Area

Table 79: WindMIL Therapeutics, Inc.. Products Portfolio

Table 80: Wuxi App Tec, Inc. Basic Information And Sales Area

Table 81: Wuxi App Tec, Inc.. Products Portfolio

Table 82: Global Market Value (USD Million) (2025-2032) By Application

Table 83: Global Market Share (%) By Application (2032)

Table 84: Global Market Value (USD Million) (2025-2032) By Types

Table 85: Global Market Share (%) By Types (2032)

Table 86: Global Cell Therapy and Tissue Engineering Market Value (USD Million) By Region

Table 87: Global Cell Therapy and Tissue Engineering Market Share (%) By Region (2025-2032)

Table 88: North America Market Value (USD Million) (2025-2032) By Country

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: North America Market Value (USD Million) (2025-2032) By Types

Table 91: Europe Market Value (USD Million) (2025-2032) By Country

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Europe Market Value (USD Million) (2025-2032) By Types

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 97: South America Market Value (USD Million) (2025-2032) By Country

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: South America Market Value (USD Million) (2025-2032) By Types

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cell Therapy and Tissue Engineering Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.00 billion
Revenue forecast in 2033	37.22 billion
Growth rate	CAGR of 15.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Betalin Therapeutics; BioCardia, Inc.; BioReliance Corporation; Biosolution Co.; Brainstorm Cell Therapeutics, Inc.; MaxCyte, Inc.; Medigene AG; MEDIPOST CO.; Mesoblast Limited; Miromatrix Medical, Inc.; MolMed S.p.A; Mustang Bio, Inc.; NantKwest, Inc.; Neuralstem, Inc.; NexImmune, Inc.; Nohla Therapeutics, Inc.; ReNeuron Group plc; Richter-Helm BioLogics GmbH & Co. KG; RoosterBio, Inc.; RoslinCT; Rubius Therapeutics, Inc.; Sangamo Therapeutics, Inc.; Voyager Therapeutics, Inc.; Waisman Biomanufacturing; WindMIL Therapeutics, Inc.; Wuxi App Tec, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options